Literature DB >> 6372564

Quinidine-induced lupus erythematosus.

S G West, M McMahon, J P Portanova.   

Abstract

A 60-year-old white man presented with a syndrome of fever, polyarthritis, pleurisy, and lymphopenia, and had a positive antinuclear antibody test (after 5 months of quinidine therapy). Quinidine-induced antinuclear autoantibodies were of the IgM and IgG classes and were directed mainly to nuclear histones, predominantly histones H1 and H2B. Antibodies to native DNA and nonhistone nuclear antigens were not seen during the patient's clinical course. Upon withdrawal of quinidine therapy, the patient had prompt improvement of clinical symptoms followed by a gradual resolution of serologic abnormalities.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6372564     DOI: 10.7326/0003-4819-100-6-840

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  6 in total

Review 1.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

2.  Acute lymphadenopathy complicating quinidine therapy.

Authors:  C P Lau; K L Wong; C K Wong; W H Leung
Journal:  Postgrad Med J       Date:  1990-05       Impact factor: 2.401

Review 3.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

Review 4.  Drug-induced lupus.

Authors:  E J Price; P J Venables
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

5.  Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex.

Authors:  R L Rubin; S A Bell; R W Burlingame
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

Review 6.  Drug-induced rheumatic syndromes. Diagnosis, clinical features and management.

Authors:  M G Cohen; M V Prowse
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 May-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.